SENS.L

Sensyne Health
Sensyne Health PLC - Results of General Meeting
11th February 2022, 17:03
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 4958B
Sensyne Health PLC
11 February 2022
 

       

 

Sensyne Health plc


("Sensyne" or the "Company")

 

Results of General Meeting

 

Oxford, U.K. 11 February 2022: Sensyne Health plc (LSE:SENS) today announces that at the General Meeting held earlier today all resolutions proposed were duly passed by shareholders.

 

The full text of the resolutions is set out in Part IV of the Notice of General Meeting in the Circular which was sent to shareholders on 26 January 2022 (the "Circular") and is available from the Company's website at https://www.sensynehealth.com/investors/shareholder-information. Terms used in this announcement shall be as defined in the Circular unless the context requires otherwise.

 

Voting on the resolutions was conducted by way of a poll and a summary of the votes received is as follows:

 

Res No.

Votes For

%

Votes Against

%

Votes Total

% of ISC

Votes Withheld*

1.     Authority to issue Warrants

115,357,952

99.98%

28,664

0.02%

115,386,616

70.02

36,007

2.     Disapply pre-emption rights for Warrants

115,351,779

99.97%

34,837

0.03%

115,386,616

70.02

36,007

3.     General authority to allot securities

115,350,817

99.97%

35,819

0.03%

115,386,636

70.02

35,987

4.     General disapplication of pre-emption rights

102,652,017

88.96%

12,734,619

11.04%

115,386,636

70.02

35,987

 

*A vote withheld is not a vote in law and means the percentage of votes cast for and against excludes withheld votes.

 

In accordance with the terms of the Note Purchase Agreement, the Company has today issued the following Conditional Warrants to the Note Purchasers under the Financing:

 

Gatemore                    1,998,352

Lansdowne                 3,597,035

Sand Grove                 6,294,813

Peel Hunt                    799,341

 

 

 

 

-ENDS-

Notes for editors:

About Sensyne Health: https://www.sensynehealth.com/

Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems.  The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organisations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

Contact details:

Sensyne Health


 

Lord (Paul) Drayson PhD FREng, Chief Executive Officer

Dr Richard Pye, Chief Financial Officer

+44 (0) 330 058 1845

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+ 44 (0) 20 7418 8900

 

Dr Christopher Golden

James Steel

 


 

Liberum (Joint Broker)


Phil Walker

William Hall

+ 44 (0) 20 3100 2000

Consilium Strategic Communications


Mary-Jane Elliott

Jessica Hodgson

CSCSensynehealth@consilium-comms.com

+44 (0) 7780 600290

SternIR


Julie Seidel

Julie.seidel@sternir.com

 +1 (212) 362 1200

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMQFLFFLLLEBBK ]]>
TwitterFacebookLinkedIn